ppodhajski
Senior Member
- Messages
- 243
- Location
- Chapel Hill, NC
Curious if some of you, specifically the ones with autoimmune issues, can look up this SNP
IDO2 R248W
https://www.23andme.com/you/explorer/snp/?snp_name=rs10109853
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238401/
IDO degrades tryptophan to produce kynuremic acid and finaly NAD (Niacin). And it uses iron as a cofactor
http://www.uniprot.org/uniprot/Q6ZQW0
I am heterozygous for this SNP; CT and apparently it means a 90% reduction in enzyme activity! Which means I might need more iron, which is also interesting since I am a hemochromotosis carrier.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115848
The finding that one of the IDO2 minor allele variants conferred CD risk is provocative, particularly given that this SNP, rs10109853 (R248W), confers a 90% reduction in enzymatic activity
http://www.researchgate.net/publica...ase_2_genotype_with_specific_immune_responses
Interestingly, we found a higher number of immune responses against
IDO2 in patients homozygous for the 248W giving reduction in IDO2 activity compared with the 248R. Hence,
spontaneous immune responses against IDO2 seem to be correlated with reduced enzymatic activity of IDO2.
Apparently, however, my SNP with the rare allele is protective against cancer and chron's.
http://pharmaceuticalintelligence.c...ostasis-of-immune-responses-for-good-and-bad/
Human tumor cells constitutively produce TDO also contributes to production of Kyn as an endogenous ligand of the AhR (75; 27). Degradation of tryptophan by IDO1/2 in tumors and tumor-draining lymph nodes occur. As a result, there are animal studies and Phase I/II clinical trials to inhibit the IDO1/2 to prevent cancer and poor prognosis (NewLink Genetics Corp. NCT00739609, 2007).
But maybe this is why iron could play a role in cancer?
http://www.ncbi.nlm.nih.gov/pubmed/8664805
Here is a long article:
http://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1067&context=mifp
IDO2 R248W
https://www.23andme.com/you/explorer/snp/?snp_name=rs10109853
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238401/
IDO degrades tryptophan to produce kynuremic acid and finaly NAD (Niacin). And it uses iron as a cofactor
http://www.uniprot.org/uniprot/Q6ZQW0
I am heterozygous for this SNP; CT and apparently it means a 90% reduction in enzyme activity! Which means I might need more iron, which is also interesting since I am a hemochromotosis carrier.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115848
The finding that one of the IDO2 minor allele variants conferred CD risk is provocative, particularly given that this SNP, rs10109853 (R248W), confers a 90% reduction in enzymatic activity
http://www.researchgate.net/publica...ase_2_genotype_with_specific_immune_responses
Interestingly, we found a higher number of immune responses against
IDO2 in patients homozygous for the 248W giving reduction in IDO2 activity compared with the 248R. Hence,
spontaneous immune responses against IDO2 seem to be correlated with reduced enzymatic activity of IDO2.
Apparently, however, my SNP with the rare allele is protective against cancer and chron's.
http://pharmaceuticalintelligence.c...ostasis-of-immune-responses-for-good-and-bad/
Human tumor cells constitutively produce TDO also contributes to production of Kyn as an endogenous ligand of the AhR (75; 27). Degradation of tryptophan by IDO1/2 in tumors and tumor-draining lymph nodes occur. As a result, there are animal studies and Phase I/II clinical trials to inhibit the IDO1/2 to prevent cancer and poor prognosis (NewLink Genetics Corp. NCT00739609, 2007).
But maybe this is why iron could play a role in cancer?
http://www.ncbi.nlm.nih.gov/pubmed/8664805
Here is a long article:
http://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1067&context=mifp